Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Aldosterone in renal disease.

Hassan N Ibrahim¹, Thomas H Hostetter

¹Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis 55455, USA. ibrah007@umn.edu

Current Opinion in Nephrology and Hypertension

|February 18, 2003

Summary

Aldosterone antagonism provides additional benefits beyond current treatments for kidney disease progression. Further long-term studies are needed to confirm its effectiveness and safety, particularly regarding hyperkalemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

For-Profit Dialysis and Academic Neglect Are Undermining Dialysis Research in the United States.

Journal of the American Society of Nephrology : JASN·2026

Same author

A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis.

Kidney international reports·2024

Same author

COVID-19 Vaccine Seroresponse Based on The Timing of The Primary Series; Pre- versus Post-Renal Transplantation.

Clinical transplantation·2023

Same author

Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study.

BMJ (Clinical research ed.)·2023

Same author

Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023

Same author

Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.

Environmental toxicology and pharmacology·2023

Area of Science:

Nephrology
Endocrinology
Cardiovascular Medicine

Background:

Renin-angiotensin-aldosterone system (RAAS) inhibitors improve outcomes in intrinsic renal diseases.
Current RAAS inhibition therapies offer incomplete renoprotection.
Exploring alternative pathways like aldosterone is crucial for optimal kidney disease management.

Purpose of the Study:

To review the role of aldosterone in renal disease progression.
To discuss the therapeutic potential of aldosterone antagonism.
To evaluate the benefits of mineralocorticoid receptor blockers in nephrology.

Main Methods:

Review of experimental evidence linking aldosterone to renal pathology.
Analysis of clinical study results from mineralocorticoid receptor antagonist trials.

Related Experiment Videos

Main Results:

Experimental data support aldosterone's contribution to renal injury.
Clinical studies demonstrate mineralocorticoid receptor blockers yield significant antiproteinuric effects.
Aldosterone antagonism complements existing therapies like ACE inhibitors.

Conclusions:

Aldosterone antagonism offers additional antiproteinuric benefits.
Further long-term trials are essential to establish efficacy and safety.
Hyperkalemia risk requires careful monitoring in aldosterone antagonism therapy.